Skip to main content
Psychedex

1Provenance card

the boundary, as counts

Sources

3712 with DOI

1 strong · 22 moderate · 14 weak

Compilations

12026-04-25T21:51:32.798Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

32last ruled 2026-06-04

0 awaiting a ruling

Issued documents

52026-10-19T20:33:41.020Z

notice · info card · emergency

Searches

221 with no results

queries and counts on the build

Claims checked

11193 supported

93 supported · 18 not

Correspondence

0received

consent field ships in Phase 4

Edges

328

derivations recorded for this entity

Complete over 37 sources, 1 compilation, and 32 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/pma/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued info_card
  2. 2026-10-19issueIssued notice
  3. 2026-10-02srcEffect of Some Psychoactive Drugs Used as 'Legal Highs' on Brain Neurotransmitters
  4. 2026-10-02srcThe PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications
  5. 2026-10-02srcA fatal case of paramethoxyamphetamine poisoning and its detection in hair.
  6. 2026-10-02srcMedicolegal aspects of PMA-related deaths.
  7. 2026-10-02srcMonoamine transporter and receptor interaction profiles of a new series of designer cathinones
  8. 2026-10-02srcEffects of para-methoxyamphetamine (PMA) on agonistic encounters between male mice.
  9. 2026-10-02srcIncidence of rhabdomyolysis occurrence in psychoactive substances intoxication: a systematic review and meta-analysis.
  10. 2026-10-02srcStudies on Para-Methoxymethamphetamine (PMMA) Metabolite Pattern and Influence of CYP2D6 Genetics in Human Liver Microsomes and Authentic Samples from Fatal PMMA Intoxications
  11. 2026-10-02srcOverview of amphetamine-type stimulant mortality data--UK, 1997-2007.
  12. 2026-10-02srcThe Non-Peptide Arginine-Vasopressin v1a Selective Receptor Antagonist, SR49059, Blocks the Rewarding, Prosocial, and Anxiolytic Effects of 3,4-Methylenedioxymethamphetamine and Its Derivatives in Zebra Fish.
  13. 2026-10-02srcNovel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling
  14. 2026-10-02srcDeaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series
  15. 2026-10-02srcDancing with 'death': p-methoxyamphetamine overdose and its acute management.
  16. 2026-10-02srcAnise oil as para-methoxyamphetamine (PMA) precursor.
  17. 2026-10-02srcThree fatal cases of PMA and PMMA poisoning in Denmark.
  18. 2026-10-02srcA fatal paramethoxymethamphetamine intoxication
  19. 2026-10-02srcParamethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects.
  20. 2026-10-02srcP-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine.
  21. 2026-10-02srcThe reinforcing and discriminative stimulus properties of para-ethoxy- and para-methoxyamphetamine.
  22. 2026-10-02srcEffects of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemide.
  23. 2026-10-02srcDifferences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
  24. 2026-10-02srcRepeated administration of the substituted amphetamine p-methoxyamphetamine produces reductions in cortical 5-HT transporter binding but not 5-HT content, unlike 3,4-methylenedioxyamethamphetamine.
  25. 2026-10-02srcThe effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain.
  26. 2026-10-02srcThe effects of co-administration of 3,4-methylenedioxymethamphetamine ('ecstasy') or para-methoxyamphetamine and moclobemide at elevated ambient temperatures on striatal 5-HT, body temperature and behavior in rats.
  27. 2026-10-02srcPharmacological and behavioral determinants of cocaine, methamphetamine, 3,4-methylenedioxymethamphetamine, and para-methoxyamphetamine-induced hyperthermia.
  28. 2026-10-02srcPotentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
  29. 2026-10-02srcp-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo.
  30. 2026-10-02srcThe stimulus properties of para-methoxyamphetamine: a nonessential serotonergic component.
  31. 2026-10-02srcComparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.
  32. 2026-10-02srcEffects of some phenylethylamines in rhesus monkeys trained to discriminate (+)-amphetamine from saline.
  33. 2026-10-02srcAmphetamine derivative fatalities in South Australia--is 'Ecstasy' the culprit?
  34. 2026-10-02srcPMA and PMMA
  35. 2026-10-02srcUK Misuse of Drugs Act 1971, Modification Order 1977 (S.I. 1977/1243)
  36. 2026-10-02srcDEA Scheduling: PMA as Schedule I hallucinogen (38 FR 26447, July 2, 1973)
  37. 2026-10-02srcPubChem Compound: (±)-p-Methoxyamphetamine
  38. 2026-10-02srcPMA legal status
  39. 2026-10-02srcPMMA/PMA - History
  40. 2026-09-04issueIssued emergency
  41. 2026-09-04issueIssued info_card
  42. 2026-09-04issueIssued notice
  43. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  44. 2026-06-04publicationPublication — backfill
  45. 2026-04-25revisionRevision 1
  46. 2026-04-25absenceSearched ClinicalTrials.gov for "para-methoxyamphetamine PMA" — no results
  47. 2026-04-25genGeneration — pipeline-v5pipeline-v5
  48. 2026-04-25rungeneration run

The same entries, as forms: six forms.